The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from its ...

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to ...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and ...

Investors appear enthused by BioAge’s focus on the red-hot obesity drug space, where both Novo Nordisk and Eli ... in two Phase II trials designed to assess the oral apelin receptor (APJ) agonist’s ...

Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.

A new study shows semaglutide medications, such as Ozempic and Wegovy, may be effective in treating hidradenitis suppurativa ...

Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.

Rivus’s lead drug is being studied in obesity-related diseases. Last week the company presented mid-stage results for the oral medicine, dubbed HU6, in patients with obesity-related heart failure. The ...

Biomed Industries, Inc- logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. Announces Positive Phase I R ...